Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total transaction of $636,340.00. Following the completion of the sale, the director directly owned 1,782 shares in the company, valued at $566,978.94. This represents a 52.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Martine Zimmermann also recently made the following trade(s):
- On Thursday, September 10th, Martine Zimmermann sold 1,200 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total transaction of $342,000.00.
Ligand Pharmaceuticals Stock Performance
LGND opened at $298.71 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The company has a market cap of $5.97 billion, a price-to-earnings ratio of 133.35, a PEG ratio of 5.13 and a beta of 1.16. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The firm’s fifty day simple moving average is $302.35 and its two-hundred day simple moving average is $259.60.
Wall Street Analysts Forecast Growth
LGND has been the subject of a number of research analyst reports. Oppenheimer reissued an “outperform” rating and set a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd. Barclays lifted their price target on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 11th. Royal Bank Of Canada boosted their price target on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Citigroup increased their price objective on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, Weiss Ratings lowered Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $355.38.
Check Out Our Latest Stock Report on Ligand Pharmaceuticals
Hedge Funds Weigh In On Ligand Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Ligand Pharmaceuticals during the 2nd quarter worth approximately $27,000. Jacobi Capital Management LLC acquired a new position in Ligand Pharmaceuticals in the third quarter valued at approximately $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Ligand Pharmaceuticals in the second quarter valued at approximately $75,000. MCF Advisors LLC grew its position in Ligand Pharmaceuticals by 118.9% in the second quarter. MCF Advisors LLC now owns 243 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 132 shares during the period. Finally, Covestor Ltd grew its position in Ligand Pharmaceuticals by 49.8% in the third quarter. Covestor Ltd now owns 337 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 112 shares during the period. 91.28% of the stock is currently owned by institutional investors and hedge funds.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Recommended Stories
- Five stocks we like better than Ligand Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
